Results 191 to 200 of about 48,812 (228)

Tumor microenvironment and signaling pathways in melanoma brain metastasis. [PDF]

Ann Transl Med
Rosell R, González-Cao M, Olmo-González D, Hold E, Molina-Vila MÁ.   +4 more
europepmc   +1 more source

Early-Onset Vogt-Koyanagi-Harada-Like Syndrome After Combined Ipilimumab and Nivolumab for Metastatic Melanoma: A Case Report. [PDF]

Cureus
Etheve F, Hainaut E, Boutin D, Riviere R.   +3 more
europepmc   +1 more source

Predicting immune-related thyroiditis using polygenic risk scores in patients with advanced melanoma. [PDF]

J Immunother Cancer
Tarhini AA, Khaksar MA, Chen Z, Lee SJ, Stephen Hodi F, Li T, Yoder SJ, Streicher H, Sondak VK, Kirkwood JM, Wang X, Kanetsky PA.   +11 more
europepmc   +1 more source

Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies

Annals of Oncology, 2014
In phase II studies, ipilimumab continues to demonstrate durable, long-term survival at a follow-up of 5-6 years in a proportion of patients with advanced melanoma.
Bart Neyns, J D Wolchok, J D Wolchok
exaly   +2 more sources

Ipilimumab and radiation therapy for melanoma brain metastases [PDF]

Cancer Medicine, 2013
Ipilimumab, an antibody that enhances T‐cell activation, may augment immunogenicity of tumor cells that are injured by radiation therapy. We hypothesized that patients with melanoma brain metastasis treated with both ipilimumab and radiotherapy would ...
Michael Bassetti, Christina Tsien, Brady T. West   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Ipilimumab

Reactions Weekly, 2017
  +10 more sources

Ipilimumab

Reactions Weekly, 2018
  +7 more sources